BioSpace News Archive

TAI Diagnostics Announces New Publication in the Journal, Pediatric Transplantation

BioInvent International AB announces that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of BioInvent’s BI-1206, one of its proprietary anti-FcγRllB antibodies and MSD’s anti-PD-1 therapy, KEYTRUDA® in a Phase l/lla clinical trial for patients with solid tumors.

The press conference held in connection with the publication of Essity’s Year-end Report for 2019 will also be available via webcast and it is possible to join by phone.

Medivir AB announces that the first patient has been enrolled and is being dosed with remetinostat gel 1% in an investigator-initiated phase II clinical study in patients with squamous cell carcinoma.

OBI Pharma announced the initiation of a Phase 1/2 clinical trial of OBI-999, an antibody drug conjugate targeting Globo H, a glycolipid antigen overexpressed in multiple tumor types.

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

Chondrial Therapeutics announced that the first patients have been dosed in a Phase 1 clinical trial to evaluate the safety and tolerability of single ascending doses of CTI-1601.

Solid Biosciences Inc. (Nasdaq: SLDB) today announced biomarker data from two patients dosed in the second cohort of IGNITE DMD, its Phase I/II study of SGT-001

IZI Medical Products, LLC (“IZI”), a leading interventional radiology medical device company and portfolio company of Shore Capital Partners, LLC (“Shore”), is pleased to announce it has acquired RadioMed, the manufacturer of VISICOIL™ implantable fiducial markers, from IBA S.A.

Eli Lilly and Company (NYSE: LLY) announced today the launch of TRIUMPH, a long-term, real-world evidence study of Emgality® (galcanezumab-gnlm).